rBCG30-induced immunity and cross-protection against Mycobacterium leprae challenge are enhanced by boosting with the Mycobacterium tuberculosis 30-kilodalton antigen 85B

Infection and Immunity

Volumn 82, Issue 9, 2014, Pages 3900-3909

  Gillis, Thomas P ^a   Tullius, Michael V ^b   Horwitz, Marcus A ^b  

^a LOUISIANA STATE UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG 3O VACCINE; BCG VACCINE; GAMMA INTERFERON; INTERLEUKIN 2; MYCOBACTERIUM ANTIGEN; SECRETORY PROTEIN ANTIGEN 85B; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BCG VACCINATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; COMPARATIVE STUDY; CONTROLLED STUDY; CROSS PROTECTION; DRUG EFFICACY; FEMALE; FOOT PAD; IMMUNE RESPONSE; LIMIT OF DETECTION; MOUSE; MYCOBACTERIUM LEPRAE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SPLEEN CELL;

ACYLTRANSFERASES; ANIMALS; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; BCG VACCINE; CD4-POSITIVE T-LYMPHOCYTES; CROSS PROTECTION; FEMALE; IMMUNIZATION; LEPROSY; MICE; MICE, INBRED BALB C; MYCOBACTERIUM BOVIS; MYCOBACTERIUM LEPRAE; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS; TUBERCULOSIS VACCINES; VACCINATION;

EID: 84906070147     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.01499-13     Document Type: Article

References (50)

1. World Health Organization. 2013. Global leprosy: update on the 2012 situation. Wkly. Epidemiol. Rec. 88:365-379.
2. Setia MS, Steinmaus C, Ho CS, Rutherford GW. 2006. The role of BCG in prevention of leprosy: a meta-analysis. Lancet Infect. Dis. 6:162-170. http://dx.doi.org/10.1016/S1473-3099(06)70412-1.
3. Merle CS, Cunha SS, Rodrigues LC. 2010. BCG vaccination and leprosy protection: review of current evidence and status of BCG in leprosy control. Expert Rev. Vaccines 9:209-222. http://dx.doi.org/10.1586/erv.09.161.
4. Duthie MS, Gillis TP, Reed SG. 2011. Advances and hurdles on the way toward a leprosy vaccine. Hum. Vaccines 7:1172-1183. http://dx.doi.org/10.4161/hv.7.11.16848.
5. Horwitz MA, Harth G. 2003. A new vaccine against tuberculosis affords greater survival after challenge than the current vaccine in the guinea pig model of pulmonary tuberculosis. Infect. Immun. 71:1672-1679. http://dx.doi.org/10.1128/IAI.71.4.1672-1679.2003.
6. Horwitz MA, Harth G, Dillon BJ, Maslesa-Galic S. 2000. Recombinant bacillus Calmette-Guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proc. Natl. Acad. Sci. U. S. A. 97:13853-13858. http://dx.doi.org/10.1073/pnas.250480397.
7. Zhang T, Zhang M, Rosenthal IM, Grosset JH, Nuermberger EL. 2009. Short-course therapy with daily rifapentine in a murine model of latent tuberculosis infection. Am. J. Respir. Crit. Care Med. 180:1151-1157. http://dx.doi.org/10.1164/rccm.200905-0795OC.
8. Tullius MV, Harth G, Maslesa-Galic S, Dillon BJ, Horwitz MA. 2008. A replication-limited recombinant Mycobacterium bovis BCG vaccine against tuberculosis designed for human immunodeficiency viruspositive persons is safer and more efficacious than BCG. Infect. Immun. 76:5200-5214. http://dx.doi.org/10.1128/IAI.00434-08.
9. Horwitz MA, Harth G, Dillon BJ, Maslesa-Galic S. 2006. A novel live recombinant mycobacterial vaccine against bovine tuberculosis more potent than BCG. Vaccine 24:1593-1600. http://dx.doi.org/10.1016/j.vaccine.2005.10.002.
10. Rizzi C, Bianco MV, Blanco FC, Soria M, Gravisaco MJ, Montenegro V, Vagnoni L, Buddle B, Garbaccio S, Delgado F, Leal KS, Cataldi AA, Dellagostin OA, Bigi F. 2012. Vaccination with a BCG strain overexpressing Ag85B protects cattle against Mycobacterium bovis challenge. PLoS One 7:e51396. http://dx.doi.org/10.1371/journal.pone.0051396.
11. Hoft DF, Blazevic A, Abate G, Hanekom WA, Kaplan G, Soler JH, Weichold F, Geiter L, SadoffJC, Horwitz MA. 2008. A new recombinant bacille Calmette-Guerin vaccine safely induces significantly enhanced tuberculosis-specific immunity in human volunteers. J. Infect. Dis. 198: 1491-1501. http://dx.doi.org/10.1086/592450.
12. Tullius MV, Horwitz MA. 2011. New generation BCG vaccines, p 119-169. In Dormitzer PR, Mandl CW, Rappuoli R (ed), Replicating vaccines: a new generation. Springer Basel AG, Basel, Switzerland.
13. Truman RW, Krahenbuhl JL. 2001. Viable M. leprae as a research reagent. Int. J. Lepr. Other Mycobact. Dis. 69:1-12.
14. Harth G, Lee BY, Horwitz MA. 1997. High-level heterologous expression and secretion in rapidly growing nonpathogenic mycobacteria of four major Mycobacterium tuberculosis extracellular proteins considered to be leading vaccine candidates and drug targets. Infect. Immun. 65:2321-2328.
15. Horwitz MA, Lee BW, Dillon BJ, Harth G. 1995. Protective immunity against tuberculosis induced by vaccination with major extracellular proteins of Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. U. S. A. 92: 1530-1534. http://dx.doi.org/10.1073/pnas.92.5.1530.
16. Shepard CC, Walker LL, Van Landingham RM. 1978. Immunity to Mycobacterium leprae infections induced in mice by BCG vaccination at different times before or after challenge. Infect. Immun. 19:391-394.
17. Shepard CC. 1960. The experimental disease that follows the injection of human leprosy bacilli into foot-pads of mice. J. Exp. Med. 112:445-454. http://dx.doi.org/10.1084/jem.112.3.445.
18. Blander SJ, Horwitz MA. 1989. Vaccination with the major secretory protein of Legionella pneumophila induces cell-mediated and protective immunity in a guinea pig model of Legionnaires' disease. J. Exp. Med. 169:691-705. http://dx.doi.org/10.1084/jem.169.3.691.
19. Blander SJ, Horwitz MA. 1991. Vaccination with the major secretory protein of Legionella induces humoral and cell-mediatedimmuneresponses and protective immunity across different serogroups of Legionella pneumophila and different species of Legionella. J. Immunol. 147:285-291.
20. Ohara N, Matsuoka M, Nomaguchi H, Naito M, Yamada T. 2000. Inhibition of multiplication of Mycobacterium leprae in mouse foot pads by recombinant bacillus Calmette-Guerin (BCG). Vaccine 18:1294-1297. http://dx.doi.org/10.1016/S0264-410X(99)00420-X.
21. Ohara N, Matsuoka M, Nomaguchi H, Naito M, Yamada T. 2001. Protective responses against experimental Mycobacterium leprae infection in mice induced by recombinant bacillus Calmette-Guerin overproducing three putative protective antigen candidates. Vaccine 19:1906-1910. http://dx.doi.org/10.1016/S0264-410X(00)00439-4.
22. Maeda Y, Tamura T, Matsuoka M, Makino M. 2009. Inhibition of the multiplication of Mycobacterium leprae by vaccination with a recombinant M. bovis BCG strain that secretes major membrane protein II in mice. Clin. Vaccine Immunol. 16:1399-1404. http://dx.doi.org/10.1128/CVI.00203-09.
23. Belisle JT, Vissa VD, Sievert T, Takayama K, Brennan PJ, Besra GS. 1997. Role of the major antigen of Mycobacterium tuberculosis in cell wall biogenesis. Science 276:1420-1422. http://dx.doi.org/10.1126/science.276.5317.1420.
24. Anderson DH, Harth G, Horwitz MA, Eisenberg D. 2001. An interfacial mechanism and a class of inhibitors inferred from two crystal structures of the Mycobacterium tuberculosis 30 kDa major secretory protein (antigen 85B), a mycolyl transferase. J. Mol. Biol. 307:671-681. http://dx.doi.org/10.1006/jmbi.2001.4461.
25. Ronning DR, Klabunde T, Besra GS, Vissa VD, Belisle JT, Sacchettini JC. 2000. Crystal structure of the secreted form of antigen 85C reveals potential targets for mycobacterial drugs and vaccines. Nat. Struct. Biol. 7:141-146. http://dx.doi.org/10.1038/72413.
26. Lee BY, Horwitz MA. 1995. Identification of macrophage and stressinduced proteins of Mycobacterium tuberculosis. J. Clin. Invest. 96:245-249. http://dx.doi.org/10.1172/JCI118028.
27. D'Souza S, Rosseels V, Romano M, Tanghe A, Denis O, Jurion F, Castiglione N, Vanonckelen A, Palfliet K, Huygen K. 2003. Mapping of murine Th1 helper T-cell epitopes of mycolyl transferases Ag85A, Ag85B, and Ag85C from Mycobacterium tuberculosis. Infect. Immun. 71:483-493. http://dx.doi.org/10.1128/IAI.71.1.483-493.2003.
28. Horwitz MA, Harth G, Dillon BJ, Maslesa-Galic S. 2005. Enhancing the protective efficacy of Mycobacterium bovis BCG vaccination against tuberculosis by boosting with the Mycobacterium tuberculosis major secretory protein. Infect. Immun. 73:4676-4683. http://dx.doi.org/10.1128/IAI.73.8.4676-4683.2005.
29. Breiman RF, Horwitz MA. 1987. The major secretory protein of Legionella pneumophila stimulates proliferation of splenic lymphocyte from immunized guinea pigs. Clin. Res. 35:469A.
30. Egen JG, Rothfuchs AG, Feng CG, Horwitz MA, Sher A, Germain RN. 2011. Intravital imaging reveals limited antigen presentation and T cell effector function in mycobacterial granulomas. Immunity 34:807-819. http://dx.doi.org/10.1016/j.immuni.2011.03.022.
31. Pal PG, Horwitz MA. 1992. Immunization with extracellular proteins of Mycobacterium tuberculosis induces cell-mediated immune responses and substantial protective immunity in a guinea pig model of pulmonary tuberculosis. Infect. Immun. 60:4781-4792.
32. Jia Q, Bowen R, Sahakian J, Dillon BJ, Horwitz MA. 2013. A heterologous prime-boost vaccination strategy comprising the Francisella tularensis live vaccine strain capB mutant and recombinant attenuated Listeria monocytogenes expressing F. tularensis IglC induces potent protective immunity in mice against virulent F. tularensis aerosol challenge. Infect. Immun. 81:1550-1561. http://dx.doi.org/10.1128/IAI.01013-12.
33. Jia Q, Lee BY, Clemens DL, Bowen RA, Horwitz MA. 2009. Recombinant attenuated Listeria monocytogenes vaccine expressing Francisella tularensis IglC induces protection in mice against aerosolized type A F. tularensis. Vaccine 27:1216-1229. http://dx.doi.org/10.1016/j.vaccine.2008.12.014.
34. Doherty TM, Olsen AW, Weischenfeldt J, Huygen K, D'Souza S, Kondratieva TK, Yeremeev VV, Apt AS, Raupach B, Grode L, Kaufmann S, Andersen P. 2004. Comparative analysis of different vaccine constructs expressing defined antigens from Mycobacterium tuberculosis. J. Infect. Dis. 190:2146-2153. http://dx.doi.org/10.1086/425931.
35. Sun R, Skeiky YA, Izzo A, Dheenadhayalan V, Imam Z, Penn E, Stagliano K, Haddock S, Mueller S, Fulkerson J, Scanga C, Grover A, Derrick SC, Morris S, Hone DM, Horwitz MA, Kaufmann SH, SadoffJC. 2009. Novel recombinant BCG expressing perfringolysin O and the over-expression of key immunodominant antigens; pre-clinical characterization, safety and protection against challenge with Mycobacterium tuberculosis. Vaccine 27:4412-4423. http://dx.doi.org/10.1016/j.vaccine.2009.05.048.
36. Pym AS, Brodin P, Majlessi L, Brosch R, Demangel C, Williams A, Griffiths KE, Marchal G, Leclerc C, Cole ST. 2003. Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis. Nat. Med. 9:533-539. http://dx.doi.org/10.1038/nm859.
37. Sugawara I, Sun L, Mizuno S, Taniyama T. 2009. Protective efficacy of recombinant BCG Tokyo (Ag85A) in rhesus monkeys (Macaca mulatta) infected intratracheally with H37Rv Mycobacterium tuberculosis. Tuberculosis (Edinb.) 89:62-67. http://dx.doi.org/10.1016/j.tube.2008.09.008.
38. Sugawara I, Li Z, Sun L, Udagawa T, Taniyama T. 2007. Recombinant BCG Tokyo (Ag85A) protects cynomolgus monkeys (Macaca fascicularis) infected with H37Rv Mycobacterium tuberculosis. Tuberculosis (Edinb.) 87:518-525. http://dx.doi.org/10.1016/j.tube.2007.06.002.
39. Jain R, Dey B, Dhar N, Rao V, Singh R, Gupta UD, Katoch VM, Ramanathan VD, Tyagi AK. 2008. Enhanced and enduring protection against tuberculosis by recombinant BCG-Ag85C and its association with modulation of cytokine profile in lung. PLoS One 3:e3869. http://dx.doi.org/10.1371/journal.pone.0003869.
40. Palendira U, Spratt JM, Britton WJ, Triccas JA. 2005. Expanding the antigenic repertoire of BCG improves protective efficacy against aerosol Mycobacterium tuberculosis infection. Vaccine 23:1680-1685. http://dx.doi.org/10.1016/j.vaccine.2004.10.007.
41. Sali M, Di Sante G, Cascioferro A, Zumbo A, Nicolo C, Dona V, Rocca S, Procoli A, Morandi M, Ria F, Palu G, Fadda G, Manganelli R, Delogu G. 2010. Surface expression of MPT64 as a fusion with the PE domain of PE_PGRS33 enhances Mycobacterium bovis BCG protective activity against Mycobacterium tuberculosis in mice. Infect. Immun. 78:5202-5213. http://dx.doi.org/10.1128/IAI.00267-10.
42. Blander SJ, Szeto L, Shuman HA, Horwitz MA. 1990. An immunoprotective molecule, the major secretory protein of Legionella pneumophila, is not a virulence factor in a guinea pig model of Legionnaires' disease. J. Clin. Invest. 86:817-824. http://dx.doi.org/10.1172/JCI114779.
43. Lee BY, Horwitz MA. 1999. T-cell epitope mapping of the three most abundant extracellular proteins of Mycobacterium tuberculosis in outbred guinea pigs. Infect. Immun. 67:2665-2670.
44. Silver RF, Wallis RS, Ellner JJ. 1995. Mapping of T cell epitopes of the 30-kDa alpha antigen of Mycobacterium bovis strain bacillus Calmette-Guerin in purified protein derivative (PPD)-positive individuals. J. Immunol. 154:4665-4674.
45. Roche PW, Peake PW, Billman-Jacobe H, Doran T, Britton WJ. 1994. T-cell determinants and antibody binding sites on the major mycobacterial secretory protein MPB59 of Mycobacterium bovis. Infect. Immun. 62:5319-5326.
46. Horwitz MA. 2005. Recombinant BCG expressing Mycobacterium tuberculosis major extracellular proteins. Microbes Infect. 7:947-954. http://dx.doi.org/10.1016/j.micinf.2005.04.002.
47. Schlesinger LS, Bellinger-Kawahara CG, Payne NR, Horwitz MA. 1990. Phagocytosis of Mycobacterium tuberculosis is mediated by human monocyte complement receptors and complement component C3. J. Immunol. 144:2771-2780.
48. Schlesinger LS, Horwitz MA. 1990. Phagocytosis of leprosy bacilli is mediated by complement receptors CR1 and CR3 on human monocytes and complement component C3 in serum. J. Clin. Invest. 85:1304-1314. http://dx.doi.org/10.1172/JCI114568.
49. Maglione PJ, Xu J, Chan J. 2007. B cells moderate inflammatory progression and enhance bacterial containment upon pulmonary challenge with Mycobacterium tuberculosis. J. Immunol. 178:7222-7234. http://dx.doi.org/10.4049/jimmunol.178.11.7222.
50. Kozakiewicz L, Chen Y, Xu J, Wang Y, Dunussi-Joannopoulos K, Ou Q, Flynn JL, Porcelli SA, Jacobs WR, Jr, Chan J. 2013. B cells regulate neutrophilia during Mycobacterium tuberculosis infection and BCG vaccination by modulating the interleukin-17 response. PLoS Pathog. 9:e1003472. http://dx.doi.org/10.1371/journal.ppat.1003472.